Major Depressive Disorder Pipeline | Clinical Trials and Key Companies – GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies

DelveInsight Business Research LLP

DelveInsight’s, “Major Depressive Disorder – Pipeline Insight, 2023,” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Major Depressive Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Some of the Key Highlights 

• The key companies working in the major depressive disorder pipeline include GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, and many others.
• The Key Therapies working in major depressive disorder pipeline include SAGE-217, REL-1017, Seltorexant, SPL026, SP-624, PDC-1421 and many others 

Got queries? Click here to learn more about the Major Depressive Disorder Pipeline 

Major Depressive Disorder Overview

Major Depressive Disorder, also referred to as clinical depression, is a significant medical condition that can affect many areas of your life. It impacts mood and behavior as well as various physical functions, such as appetite and sleep. The exact cause of MDD isn’t known. However, there are several factors that can increase the risk of developing the condition. Symptoms must occur for a period of 2 or more weeks and at least one symptom is either a depressed mood or loss of interest or pleasure. MDD is often treated with medication and psychotherapy. Some lifestyle adjustments can also help ease certain symptoms.

DelveInsight’s report covers around 75+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration

Major Depressive Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Subcutaneous
• Intravenous
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Bispecific Antibody
• Peptides
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.

Learn more by requesting for sample @ Major Depressive Disorder Pipeline 

Major Depressive Disorder Pipeline  Key Companies  

• GH Research
• Praxis Precision Medicines
• AbbVie, 
• Gedeon Richter
• Intra-Cellular Therapies 

And many others 

Major Depressive Disorder Pipeline Therapies 

• SAGE-217
• REL-1017
•  Seltorexant
• SPL026
•  SP-624
• PDC-1421 

And many others 

Table of Contents

• Key Insights 
• Report Introduction 
•  Executive Summary of Major Depressive Disorder Pipeline 
•  Disease Background and Overview
•  Epidemiology and patient population
•  Major Depressive Disorder Pipeline  Emerging Therapies
•  Major Depressive Disorder Pipeline   Market Outlook
• Market Access and Reimbursement of Therapies
•  Appendix
• Major Depressive Disorder Pipeline    Report Methodology
•  DelveInsight Capabilities
• Disclaimer

About DelveInsight

Click here to read more about  Major Depressive Disorder Pipeline  

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services